Differential expression of mitochondrial energy metabolism profiles across the metaplasia-dysplasia-adenocarcinoma disease sequence in Barrett's oesophagus

Cancer Letters

Volumn 354, Issue 1, 2014, Pages 122-131

  Phelan, J J ^a   MacCarthy, F ^a   Feighery, R ^a   O'Farrell, N J ^a   Lynam Lennon, N ^a   Doyle, B ^a   O'Toole, D ^a   Ravi, N ^a   Reynolds, J V ^a   O'Sullivan, J ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Barrett's metaplasia; Glycolysis; Mitochondrial dysfunction; Mitochondrial energy metabolism; Oesophageal cancer; Oxidative phosphorylation

Indexed keywords

ARTICLE; ATP12A GENE; BARRETT ESOPHAGUS; CONTROLLED STUDY; COX4I2 GENE; COX8C GENE; ENERGY METABOLISM; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS DYSPLASIA; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METAPLASIA; MICROARRAY ANALYSIS; MITOCHONDRIAL RESPIRATION; ONCOGENE; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; ADENOCARCINOMA; BARRETT'S METAPLASIA; BIOPSY; CHEMISTRY; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; MITOCHONDRIAL DYSFUNCTION; MITOCHONDRIAL ENERGY METABOLISM; MITOCHONDRION; OESOPHAGEAL CANCER; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ATP12A PROTEIN, HUMAN; COX4I2 PROTEIN, HUMAN; COX8C PROTEIN, HUMAN; CYTOCHROME C OXIDASE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; OXYGEN;

BARRETT'S METAPLASIA; GLYCOLYSIS; MITOCHONDRIAL DYSFUNCTION; MITOCHONDRIAL ENERGY METABOLISM; OESOPHAGEAL CANCER; OXIDATIVE PHOSPHORYLATION;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BIOPSY; CELL LINE, TUMOR; DISEASE PROGRESSION; ELECTRON TRANSPORT COMPLEX IV; ENERGY METABOLISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; METAPLASIA; MITOCHONDRIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXYGEN; PHOSPHORYLATION;

EID: 84910002298     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.035     Document Type: Article

References (32)

1. Su Z., Gay L.J., Strange A., Palles C., Band G., Whiteman D.C., et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat. Genet 2012, 44:1131-1136.
2. Hvid-Jensen F., Pedersen L., Drewes A.M., Sorensen H.T., Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N. Engl. J. Med 2011, 365:1375-1383.
3. Ronkainen J., Aro P., Storskrubb T., Johansson S.E., Lind T., Bolling-Sternevald E., et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005, 129:1825-1831.
4. Jankowski J., Barr H., Wang K., Delaney B. Diagnosis and management of Barrett's oesophagus. BMJ 2010, 341:c4551.
5. Reynolds J.V., Donohoe C.L., McGillycuddy E., Ravi N., O'Toole D., O'Byrne K., et al. Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: lessons from the experience of a high-volume center. J. Thorac. Cardiovasc. Surg 2012, 143:1130-1137.e1.
6. Gogvadze V., Zhivotovsky B., Orrenius S. The Warburg effect and mitochondrial stability in cancer cells. Mol. Aspects Med 2010, 31:60-74.
7. Isidoro A., Martinez M., Fernandez P.L., Ortega A.D., Santamaria G., Chamorro M., et al. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem. J. 2004, 378:17-20.
8. Sifroni K.G., Damiani C.R., Stoffel C., Cardoso M.R., Ferreira G.K., Jeremias I.C., et al. Mitochondrial respiratory chain in the colonic mucosal of patients with ulcerative colitis. Mol. Cell. Biochem 2010, 342:111-115.
9. Cuezva J.M., Krajewska M., de Heredia M.L., Krajewski S., Santamaria G., Kim H., et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002, 62:6674-6681.
10. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
11. Weinberg F., Chandel N.S. Mitochondrial metabolism and cancer. Ann. N. Y. Acad. Sci 2009, 1177:66-73.
12. Fogal V., Richardson A.D., Karmali P.P., Scheffler I.E., Smith J.W., Ruoslahti E. Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol. Cell. Biol 2010, 30:1303-1318.
13. Ericson N.G., Kulawiec M., Vermulst M., Sheahan K., O'Sullivan J., Salk J.J., et al. Decreased mitochondrial DNA mutagenesis in human colorectal cancer. PLoS Genet 2012, 8:e1002689.
14. Tennant D.A., Duran R.V., Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 2010, 10:267-277.
15. De Meirleir L., Seneca S., Lissens W., De Clercq I., Eyskens F., Gerlo E., et al. Respiratory chain complex V deficiency due to a mutation in the assembly gene ATP12. J. Med. Genet 2004, 41:120-124.
16. Streif D., Iglseder E., Hauser-Kronberger C., Fink K.G., Jakab M., Ritter M. Expression of the non-gastric H+/K+ ATPase ATP12A in normal and pathological human prostate tissue. Cell. Physiol. Biochem 2011, 28:1287-1294.
17. Huttemann M., Lee I., Gao X., Pecina P., Pecinova A., Liu J., et al. Cytochrome c oxidase subunit 4 isoform 2-knockout mice show reduced enzyme activity, airway hyporeactivity, and lung pathology. FASEB J. 2012, 26:3916-3930.
18. Baracca A., Chiaradonna F., Sgarbi G., Solaini G., Alberghina L., Lenaz G. Mitochondrial Complex I decrease is responsible for bioenergetic dysfunction in K-ras transformed cells. Biochim. Biophys. Acta 2010, 1797:314-323.
19. Bellance N., Benard G., Furt F., Begueret H., Smolkova K., Passerieux E., et al. Bioenergetics of lung tumors: alteration of mitochondrial biogenesis and respiratory capacity. Int. J. Biochem. Cell Biol 2009, 41:2566-2577.
20. Bonora E., Porcelli A.M., Gasparre G., Biondi A., Ghelli A., Carelli V., et al. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res 2006, 66:6087-6096.
21. Simonnet H., Alazard N., Pfeiffer K., Gallou C., Beroud C., Demont J., et al. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 2002, 23:759-768.
22. Simonnet H., Demont J., Pfeiffer K., Guenaneche L., Bouvier R., Brandt U., et al. Mitochondrial complex I is deficient in renal oncocytomas. Carcinogenesis 2003, 24:1461-1466.
23. Hudson E.K., Hogue B.A., Souza-Pinto N.C., Croteau D.L., Anson R.M., Bohr V.A., et al. Age-associated change in mitochondrial DNA damage. Free Radic. Res 1998, 29:573-579.
24. Isidoro A., Casado E., Redondo A., Acebo P., Espinosa E., Alonso A.M., et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 2005, 26:2095-2104.
25. Ortega A.D., Sanchez-Arago M., Giner-Sanchez D., Sanchez-Cenizo L., Willers I., Cuezva J.M. Glucose avidity of carcinomas. Cancer Lett 2009, 276:125-135.
26. Whitaker-Menezes D., Martinez-Outschoorn U.E., Flomenberg N., Birbe R.C., Witkiewicz A.K., Howell A., et al. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle 2011, 10:4047-4064.
27. Cornford P.A., Dodson A.R., Parsons K.F., Desmond A.D., Woolfenden A., Fordham M., et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000, 60:7099-7105.
28. Ruan W., Wang Y., Ma Y., Xing X., Lin J., Cui J., et al. HSP60, a protein downregulated by IGFBP7 in colorectal carcinoma. J. Exp. Clin. Cancer Res 2010, 29:41.
29. Thomas X., Campos L., Mounier C., Cornillon J., Flandrin P., Le Q.H., et al. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk. Res 2005, 29:1049-1058.
30. Liu J., Wang L.D., Sun Y.B., Li E.M., Xu L.Y., Zhang Y.P., et al. Deciphering the signature of selective constraints on cancerous mitochondrial genome. Mol. Biol. Evol 2012, 29:1255-1261.
31. Yao F., Zhao T., Zhong C., Zhu J., Zhao H. LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. Tumour Biol 2013, 34:25-31.
32. Koss K., Harrison R.F., Gregory J., Darnton S.J., Anderson M.R., Jankowski J.A. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus. J. Clin. Pathol 2004, 57:1156-1159.